HIV Infections Clinical Trial
Official title:
NIMH Collaborative HIV/STD Prevention Trial
This study will evaluate the effectiveness of a community-level HIV prevention program in promoting safer sexual behaviors and reducing the transmission of HIV/sexually transmitted diseases among at-risk populations in China, India, Peru, Russia, and Zimbabwe.
The HIV/AIDS epidemic remains largely out of control in many areas of the world, with an
estimated 2.5 million new HIV infections worldwide in 2007. Developing countries with few
economic resources and world regions undergoing difficult social transitions have been
particularly impacted by large increases in HIV and sexually transmitted disease (STD)
infections. To date, effective individual prevention approaches have not been rapid enough
to avert the epidemic in these areas and may be too resource intensive to maintain.
Behavioral HIV prevention interventions on the community level seek to reduce the prevalence
of high-risk sexual behaviors by reaching large numbers of vulnerable people in a
cost-effective and feasible manner, even in areas with limited resources. The Community
Popular Opinion Leader (C-POL) program is an HIV prevention intervention that recruits and
trains trusted opinion leaders in the community to promote safe sex behaviors through
risk-reduction conversations with peers. Implementing the C-POL program in world regions
facing significant HIV/AIDS epidemics may be the most effective means of encouraging
behavior change among members of at-risk populations and strengthening social norms to
maintain these changes. This study will evaluate the effectiveness of the C-POL program in
promoting safer sexual behaviors and reducing the transmission of HIV/STDs among at-risk
populations in China, India, Peru, Russia, and Zimbabwe.
Participation in this study will last 2 years. Initially, an ethnographic study will be
conducted to determine the HIV/STD knowledge, attitudes, and behaviors among the population
living in the target communities. Information collected via observation, focus groups, and
interviews will be used to determine the social risk groups operating within the community
and to identify and recruit the opinion leaders who are influential in these groups. Also,
an epidemiological study will be conducted to collect information on sexual behaviors and
HIV/STD rates.
A cohort of members from participating communities will first undergo baseline assessments
that will include a survey about general health and knowledge of HIV/STDs and a biological
sampling for HIV/STD testing. Participating communities will then be assigned randomly to
receive the C-POL intervention and HIV/STD educational materials or HIV/STD educational
materials alone. In communities receiving the C-POL intervention, the previously recruited
opinion leaders will be taught skills for sharing HIV risk-reduction messages in daily
conversation with peers. This training will occur over four to five weekly sessions. At
least 15% of the community population will be trained as opinion leaders. After the initial
training, opinion leaders will attend six to nine booster sessions over the next 2 years to
reinforce and support continued conversation efforts. Communities assigned to receive the
HIV/STD educational materials will receive informational materials on HIV/STDs to provide to
community members and will provide treatment or treatment referral for people with nonviral
STDs.
All participants in the baseline cohort will be asked to repeat the baseline testing 1 and 2
years later. Participants who are not able to visit a clinic for testing will be contacted
by phone to complete the baseline survey. After the 2-year assessments, the C-POL
intervention will be conducted in the communities that received educational materials only.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |